Cargando…

2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients

BACKGROUND: 16S rRNA gene-based studies report that allogeneic hematopoietic stem cell transplant (aHSCT) recipients with low bacterial diversity and certain bacteria close to engraftment have increased risk of developing acute graft-vs.-host disease (aGvHD). Using shotgun metagenomic data, we aim t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilett, Emma E, Reekie, Joanne, Jørgensen, Mette, Murray, Daniel D, Noguera, Marc, Paredes, Roger, Nørgaard, Jens C, Daugaard, Gedske, Helleberg, Marie, Lundgren, Jens, MacPherson, Cameron, Sengeløv, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810550/
http://dx.doi.org/10.1093/ofid/ofz360.2247
_version_ 1783462282903158784
author Ilett, Emma E
Reekie, Joanne
Jørgensen, Mette
Murray, Daniel D
Noguera, Marc
Paredes, Roger
Nørgaard, Jens C
Daugaard, Gedske
Helleberg, Marie
Lundgren, Jens
MacPherson, Cameron
Sengeløv, Henrik
author_facet Ilett, Emma E
Reekie, Joanne
Jørgensen, Mette
Murray, Daniel D
Noguera, Marc
Paredes, Roger
Nørgaard, Jens C
Daugaard, Gedske
Helleberg, Marie
Lundgren, Jens
MacPherson, Cameron
Sengeløv, Henrik
author_sort Ilett, Emma E
collection PubMed
description BACKGROUND: 16S rRNA gene-based studies report that allogeneic hematopoietic stem cell transplant (aHSCT) recipients with low bacterial diversity and certain bacteria close to engraftment have increased risk of developing acute graft-vs.-host disease (aGvHD). Using shotgun metagenomic data, we aim to confirm and extend these observations in a larger cohort. METHODS: Adult aHSCT recipients with stool samples collected days −30 to +100 relative to aHSCT, but prior to aGvHD, were included. One sample was selected per patient and time point: pre-aHSCT (T(1)), post-aHSCT pre-engraftment (T(2)). Complete ascertainment of aGvHD (grades ≥ 2) until day +100 was performed. Bacterial microbiome factors (α-diversity, gene richness and 16 a priori bacteria) and clinical factors were tested for associations with aGvHD across T(1:2) in univariable models. Significant factors (P < 0.1) were included in a multivariable model. RESULTS: Of 147 aHSCT recipients, 35 developed aGvHD a median of 35 days (IQR 24–51) post-aHSCT. We found that higher gene richness was significantly associated with lower aGvHD risk in T(2), but not T(1), samples (OR 0.65 (95% CI 0.42–1.00), P = 0.04 vs. OR 1.14 (95% CI 0.67–1.94), P = 0.64 per doubling of unique genes). A decreased abundance of Akkermansia muciniphila, Proteobacteria, Blautia and Gammaproteobacteria was observed in those that developed aGvHD, again in T(2) samples only (Figure 1). Among clinical factors, donor sex, donor/recipient (related/unrelated) and conditioning regimen (adjusted OR = 0.34 for non-myeloablative vs myeloablative (95% CI 0.15–0.77)) were significantly associated with aGvHD. Conditioning regimen was also strongly associated with microbiome changes; myeloablative recipients had lower gene richness and differences in bacterial abundance, including decreased abundance of aforementioned bacteria, compared with non-myeloablative recipients at T(2) (Figures 2and 3). CONCLUSION: Post-aHSCT pre-engraftment was a crucial timepoint where microbial changes, including lower gene richness and abundance of certain bacteria, were associated with development of aGvHD. Myeloablative regimes were also associated with both aGvHD and microbiome changes, suggesting that intense conditioning may affect aGvHD risk through perturbation of the gut microbiome. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810550
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68105502019-10-28 2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients Ilett, Emma E Reekie, Joanne Jørgensen, Mette Murray, Daniel D Noguera, Marc Paredes, Roger Nørgaard, Jens C Daugaard, Gedske Helleberg, Marie Lundgren, Jens MacPherson, Cameron Sengeløv, Henrik Open Forum Infect Dis Abstracts BACKGROUND: 16S rRNA gene-based studies report that allogeneic hematopoietic stem cell transplant (aHSCT) recipients with low bacterial diversity and certain bacteria close to engraftment have increased risk of developing acute graft-vs.-host disease (aGvHD). Using shotgun metagenomic data, we aim to confirm and extend these observations in a larger cohort. METHODS: Adult aHSCT recipients with stool samples collected days −30 to +100 relative to aHSCT, but prior to aGvHD, were included. One sample was selected per patient and time point: pre-aHSCT (T(1)), post-aHSCT pre-engraftment (T(2)). Complete ascertainment of aGvHD (grades ≥ 2) until day +100 was performed. Bacterial microbiome factors (α-diversity, gene richness and 16 a priori bacteria) and clinical factors were tested for associations with aGvHD across T(1:2) in univariable models. Significant factors (P < 0.1) were included in a multivariable model. RESULTS: Of 147 aHSCT recipients, 35 developed aGvHD a median of 35 days (IQR 24–51) post-aHSCT. We found that higher gene richness was significantly associated with lower aGvHD risk in T(2), but not T(1), samples (OR 0.65 (95% CI 0.42–1.00), P = 0.04 vs. OR 1.14 (95% CI 0.67–1.94), P = 0.64 per doubling of unique genes). A decreased abundance of Akkermansia muciniphila, Proteobacteria, Blautia and Gammaproteobacteria was observed in those that developed aGvHD, again in T(2) samples only (Figure 1). Among clinical factors, donor sex, donor/recipient (related/unrelated) and conditioning regimen (adjusted OR = 0.34 for non-myeloablative vs myeloablative (95% CI 0.15–0.77)) were significantly associated with aGvHD. Conditioning regimen was also strongly associated with microbiome changes; myeloablative recipients had lower gene richness and differences in bacterial abundance, including decreased abundance of aforementioned bacteria, compared with non-myeloablative recipients at T(2) (Figures 2and 3). CONCLUSION: Post-aHSCT pre-engraftment was a crucial timepoint where microbial changes, including lower gene richness and abundance of certain bacteria, were associated with development of aGvHD. Myeloablative regimes were also associated with both aGvHD and microbiome changes, suggesting that intense conditioning may affect aGvHD risk through perturbation of the gut microbiome. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810550/ http://dx.doi.org/10.1093/ofid/ofz360.2247 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ilett, Emma E
Reekie, Joanne
Jørgensen, Mette
Murray, Daniel D
Noguera, Marc
Paredes, Roger
Nørgaard, Jens C
Daugaard, Gedske
Helleberg, Marie
Lundgren, Jens
MacPherson, Cameron
Sengeløv, Henrik
2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients
title 2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients
title_full 2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients
title_fullStr 2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients
title_full_unstemmed 2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients
title_short 2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients
title_sort 2569. the gut microbiome and acute graft vs. host disease risk in hematopoietic stem cell transplantation recipients
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810550/
http://dx.doi.org/10.1093/ofid/ofz360.2247
work_keys_str_mv AT ilettemmae 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT reekiejoanne 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT jørgensenmette 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT murraydanield 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT nogueramarc 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT paredesroger 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT nørgaardjensc 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT daugaardgedske 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT hellebergmarie 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT lundgrenjens 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT macphersoncameron 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients
AT sengeløvhenrik 2569thegutmicrobiomeandacutegraftvshostdiseaseriskinhematopoieticstemcelltransplantationrecipients